Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
The study aims to evaluate arterial stiffness and endothelial function indexes and their
 relationship with clinic and laboratory varible in a group of diabetic patients in treatment
 with dulaglutide
46 patients with type 2 diabetes mellitus were recruited at the Internal Medicine with Stroke
 care ward of the University hospital of Palermo "P. Giaccone" from April 2017 to April 2018.
 For all patients treatment with dulaglutide was undertaken. As control group were recruited
 46 patients from the same ward not affected by diabetes mellitus or affected by diabetes
 mellitus but not in treatment with dulaglutide.

 The study was carried out in accordance with the principles of the Helsinki Declaration
 revised in 2001 and all patients gave their written consent to take part in this research.

 Each patient treated with dulaglutide was compared for age, sex and cardiovascular risk with
 control patients. The diagnosis of type 2 diabetes mellitus was based on the revised criteria
 of the American Diabetes Association (ADA), and using a clinical algorithm that considered
 the age of onset of the disease, the symptoms and weight present, the family history and the
 therapy practiced. Arterial hypertension was defined according to the 2017 ESC-ESH criteria.
 Dyslipidemia was defined based on total cholesterol levels> 200 mg/dl, triglycerides> 150
 mg/dl and HDL levels <40 mg/dl regardless of the patient's gender.

 Among the cases enrolled, 46 (100%) had type 2 diabetes mellitus, 37 (80.43%) had arterial
 hypertension and 26 (56.52%) hypercholesterolemia.

 Clinical and anthropometric data were collected at the time of recruitment. Blood samples
 were taken from each patient (cases and controls) to determine serum glucose, HbA1c, total
 cholesterol, HDL and LDL cholesterol, triglycerides, creatinine, and a urine sample to assess
 the presence of microalbuminuria. These withdrawals were then repeated three months and nine
 months from the time of recruitment.

 The digital endothelial function was evaluated through the RHI-pat analysis using
 Endo-PAT2000. Pulse Wave Velocity (PWV) Carotid-Femoral Pulse was measured in the supine
 position using an automatic device (SphygmoCor version 7.1) that evaluated the propagation
 time of the sphygmic wave between the carotid and femoral pulse.
Inclusion Criteria:

 -  diabetes mellitus

 Exclusion Criteria:

 -  cancer, severe ckd, end stage liver disease